Journal of comparative effectiveness research
-
Randomized Controlled Trial Multicenter Study Comparative Study
Relative effectiveness of sunitinib versus everolimus in advanced pancreatic neuroendocrine tumors: an updated matching-adjusted indirect comparison.
A matching-adjusted indirect comparison (MAIC) of sunitinib and everolimus has been previously reported based on the RADIANT-3 everolimus trial. We performed an analysis using updated overall survival (OS) data based on sunitinib's trial (A6181111). ⋯ Findings indicate comparable PFS and OS with sunitinib and everolimus.